Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: Data from a large multisite population-based candidemia surveillance program, 2008-2014

Open Forum Infectious Diseases

Volumn 2, Issue 4, 2015, Pages

  Vallabhaneni, Snigdha ^a,b   Cleveland, Angela A ^b   Farley, Monica M ^c,d   Harrison, Lee H ^e   Schaffner, William ^f   Beldavs, Zintar G ^g   Derado, Gordana ^b   Pham, Cau D ^b   Lockhart, Shawn R ^b   Smith, Rachel M ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OREGON HEALTH AUTHORITY   (United States)

Author keywords

Candida glabrata; Candidemia; Echinocandin resistance; Epidemiology; Risk factors; Transmission of drug resistance

Indexed keywords

ECHINOCANDIN;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CHILD; DISEASE SURVEILLANCE; FEMALE; GENE MUTATION; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 85014393614     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv163     Document Type: Article

References (26)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198-208.
2. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011 Clin Infect Dis 2012; 55:1352-61.
3. Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the prospective antifungal therapy (PATH) registry 2004-2008. PLoS One 2014; 9:e101510.
4. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46:120-8.
5. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
6. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150-6.
7. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PloS One 2015; 10:e0120452.
8. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724-32.
9. Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazoleresistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199-203.
10. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 2014; 20: 1833-40.
11. Beyda ND, John J, Kilic A, et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014; 59:819-25.
12. Kagan S, Ickowicz D, Shmuel M, et al. Toxicity mechanisms of Amphotericin B and Its neutralization by conjugation with arabinogalactan. Antimicrob Agents Chemother 2012; 56:5603-11.
13. Lockhart SR, Iqbal N, Cleveland AA, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two United States cities from 2008 to 2011. J Clin Microbiol 2012; 50:3435-42.
14. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition. CLSI document MM27-A3. Wayne, PA; Clinical and Laboratory Standards Institute; 2008.
15. Pham CD, Bolden CB, Kuykendall RJ, Lockhart SR. Development of a luminex-based multiplex assay for detection of mutations conferring resistance to echinocandins in Candida glabrata. J Clin Microbiol 2014; 52:790-5.
16. Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from United States population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042-7.
17. CLSI. M27-S4. Reference Method for Broth Dilution antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. CLSI document MM18-A. Wayne, PA; Clinical and Laboratory Standards Institute; 2012.
18. Fekkar A, Dannaoui E, Meyer I, et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis 2014; 33:1489-96.
19. Ruttimann S, Keck B, Hartmeier C, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004; 38:348-56.
20. Ansari F, Gray K, Nathwani D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003; 52:842-8.
21. Valerio M, Rodriguez-Gonzalez CG, Munoz P, et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014; 69:1993-9.
22. Blanchard E, Lortholary O, Boukris-Sitbon K, et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother 2011; 55:5358-61.
23. Sanguinetti M, Posteraro B, Fiori B, et al. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005; 49:668-79.
24. Malani AN, Psarros G, Malani PN, Kauffman CA. Is age a risk factor for Candida glabrata colonization? Mycoses 2011; 54:531-7.
25. Pfaller MA, Messer SA, Hollis RJ, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007 J Clin Microbiol 2009; 47:3185-90.
26. Shields RK, Nguyen MH, Press EG, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012; 56:4862-9.